# EVENET (NCT06472388)

> Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06472388
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: AC Camargo Cancer Center
- Conditions: Neuroendocrine Tumors; Progression; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Carcinoid
- Interventions: Everolimus 5 MG
- Enrollment: 100
- Primary outcome: Progression free survival rate at 12 months

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=evenet-nct06472388